Evidence map›Paper›PMID 33473182›Full record

ArticleActa pharmacologica Sinica2021

Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice.

Ling-Ling Jia, Ming Zhang, He Liu, Jia Sun, Li-Long Pan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The Nerves to Conduct a Multiple Sclerosis Crime Investigation.International journal of molecular sciences · 2021
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ling-Ling JiaWuxi School of Medicine, Jiangnan University, Wuxi, 214122, China.
Ming ZhangState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
He LiuState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China.
Jia SunState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, China. jiasun@jiangnan.edu.cn.
Li-Long PanWuxi School of Medicine, Jiangnan University, Wuxi, 214122, China. llpan@jiangnan.edu.cn.
Jiangnan University · CNState Key Laboratory of Food Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fingolimod has beneficial effects on multiple diseases, including type 1 diabetes (T1D) and numerous preclinical models of colitis. Intestinal dysbiosis and intestinal immune dysfunction contribute to disease pathogenesis of T1D. Thus, the beneficial effect of fingolimod on T1D may occur via the maintenance of intestinal homeostasis to some extent. Herein, we investigated the role of fingolimod in intestinal dysfunction in non-obese diabetic (NOD) mice and possible mechanisms. NOD mice were treated with fingolimod (1 mg · kg

Indexed as

AnimalsCD4-Positive T-LymphocytesCell MovementDiabetes Mellitus, Type 1DysbiosisFemaleFingolimod HydrochlorideGastrointestinal MicrobiomeHomeostasisHypoglycemic AgentsImmune ToleranceIntestinesMiceMice, Inbred NODPancreasSignal TransductionFingolimod HydrochlorideHypoglycemic Agentsenteric pathogensfingolimodgut barrierTLR2-NF-κB-NLRP3type 1 diabetes

Identifiers

PMID33473182
PMCPMC8463616
OpenAlexW3122903953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.